Normal view MARC view ISBD view

Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment.

MedStar author(s):

Citation: Cytotherapy. 24(9):884-891, 2022 09.PMID: 35705447Department: MedStar Georgetown University Hospital/MedStar Washington Hospital Center | Pediatrics ResidencyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Hematopoietic Stem Cell Transplantation | *Virus Diseases | Adoptive Transfer | Antiviral Agents/tu [Therapeutic Use] | Cell Engineering | Genetic Therapy | Hematopoietic Stem Cell Transplantation/ae [Adverse Effects] | Humans | Virus Diseases/et [Etiology] | Virus Diseases/pc [Prevention & Control]Year: 2022 ISSN:

1465-3249

Name of journal: CytotherapyAbstract: Despite recent advances in the field of HSCT, viral infections remain a frequent causeof morbidity and mortality among HSCT recipients. Adoptive transfer of viral specific T cells has been successfully used both as prophylaxis and treatment of viral infections in immunocompromised HSCT recipients. Increasingly, precise risk stratification of HSCT recipients with infectious complications should incorporate not only pretransplant clinical criteria, but milestones of immune reconstitution as well. These factors can better identify those at highest risk of morbidity and mortality and identify a population of HSCT recipients in whom adoptive therapy with viral specific T cells should be considered for either prophylaxis or second line treatment early after inadequate response to first line antiviral therapy. Broadening these approaches to improve outcomes for transplant recipients in countries with limited resources is a major challenge. While the principles of risk stratification can be applied, early detection of viral reactivation as well as treatment is challenging in regions where commercial PCR assays and antiviral agents are not readily available. Copyright © 2022. Published by Elsevier Inc.All authors: Abraham A, Bertaina A, Boelens JJ, Bonfim C, Ciccocioppo R, Cohen S, ISCT working committee on stem cell engineering, Prockop S, Purtill D, Ruggeri A, Russell A, Sharma A, Stanojevic M, Wynn RFiscal year: FY2023 Digital Object Identifier:

https://dx.doi.org/10.1016/j.jcyt.2022.05.010

Date added to catalog: 2022-10-20

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	35705447	Available		35705447

Despite recent advances in the field of HSCT, viral infections remain a frequent causeof morbidity and mortality among HSCT recipients. Adoptive transfer of viral specific T cells has been successfully used both as prophylaxis and treatment of viral infections in immunocompromised HSCT recipients. Increasingly, precise risk stratification of HSCT recipients with infectious complications should incorporate not only pretransplant clinical criteria, but milestones of immune reconstitution as well. These factors can better identify those at highest risk of morbidity and mortality and identify a population of HSCT recipients in whom adoptive therapy with viral specific T cells should be considered for either prophylaxis or second line treatment early after inadequate response to first line antiviral therapy. Broadening these approaches to improve outcomes for transplant recipients in countries with limited resources is a major challenge. While the principles of risk stratification can be applied, early detection of viral reactivation as well as treatment is challenging in regions where commercial PCR assays and antiviral agents are not readily available. Copyright © 2022. Published by Elsevier Inc.

English